

Effect of orforglipron versus placebo and dulaglutide on glycaemic control and body weight in patients with type 2 diabetes
In this medfyle
The study examined the efficacy of orforglipron in reducing HbA1c, fasting serum glucose, and bodyweight. Orforglipron led to clinically significant reductions in HbA1c, fasting serum glucose, and body weight with an adverse events profile consistent with other GLP-1 RAs.
Expert commentary
About this Medfyle
This is a summary of a presentation given at the EASD 2023 Annual Meeting. The content is developed by Infomedica in collaboration with the Diabetes Education Study Group (DESG).
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, Medfyle, or the DESG.
©2023 Infomedica-Medfyle. All rights reserved.